Inclusion Criteria:

- Age >18

- WHO performance status 0-2

- Life expectancy ≥ 3 months

- Patients receiving androgen-suppressive therapy in the form of chirurgical castration
by orchiectomy or pulpectomy,or medical by LHRH agonist or antagonist with or without
anti-androgen or all treatment blocking non gonadic testosterone fraction

- Resulting to testosteronemia <0,5 ng/ml

- Histologically confirmed adenocarcinomia of prostate cancer and documented hormone
independant metastatic disease - defined by: objective progression with at least one
measurable lesion and/or evaluable lesion according to RECIST criteria and /or a rise
in PSA level ("rising PSA")

- Total bilirubin ≤ upper limit of normal (ULN).

- AST and ALT ≤ 1.5 times ULN. Alkaline phosphatase ≤ 2.5 times ULN.

- Serum creatinine < 140 µmol/L or creatinine clearance > 60 mL/ min.

- Neutrophil count > 2.109 L-1.

- Platelet count ≥ 100,000/mm3.

- Hemoglobin ≥ 10 g/dL

- Not previous chemotherapy, except Estracyt

- No liver, kidney or heart failure link to treatment

- No malabsorption syndrome or disease significantly affecting gastrointestinal
function

- Prior radiotherapies are permetted withing four weeks of the first study treatment
and must be < 25 % of the bone marrow, and all adverse events must be resolved

- Prior surgery are permitted.

Exclusion Criteria:

- Age < 18

- History of psychiatric disorders including psychotic disorder, dementia or seizures
that would prohibit the understanding, observance and giving of informed consent

- Previous or concomitant other malignancies except basal or squamous cell carcinoma of
the skin or other cancer curatively treated with surgery and/or radiotherapy

- Patients should not have symptomatic brain metastasis

- Concurrent severe and/or uncontrolled co-morbid medical condition

- Malabsorption syndrome or disease significantly affecting gastro-intestinal function
or major resection of the stomach, proximal small bowel or grade > 2 dysphagia

- Patients with uncontrolled infection

- History of significant neurologic (i.e. peripheral neuropathy grade > 2 using NCI-CTC
criteria v3.0)

- Patients should not have received NSAIDs or COX2 inhibitors within the three weeks
prior to starting the study

- Treatment with any investigational drug within 30 days prior to registration

- Patients should not have current regimen containing dietary phytonutrients